Optics.org
daily coverage of the optics & photonics industry and the markets that it serves
Press Releases
Menu
Press Release

PDL BioPharma completes spin-off of Lensar

Date Announced: 07 Oct 2020

Lensar begins trading on NASDAQ.

INCLINE VILLAGE, Nev.USA -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR").

PDL stockholders received 0.075879 shares of LENSAR common stock for every one share of PDL common stock outstanding at 5:00 p.m. Eastern Time on September 22, 2020, the record date for the spin-off.  

Stockholders of PDL who have acquired shares of PDL common stock in the "regular way" market since shortly before the record date and through October 1, 2020 acquired such shares with an entitlement to receive shares of LENSAR common stock in connection with the distribution.

Stockholders of PDL who acquired their shares of PDL common stock ex-distribution during that time did so without an entitlement to receive shares of LENSAR common stock in connection with the distribution.  LENSAR shares will begin "regular way" trading on the NASDAQ Stock Market on October 2, 2020.

About PDL BioPharma, Inc.

Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.  PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases.  In 2006, the Company changed its name to PDL BioPharma, Inc.

As of December 2019, PDL ceased making additional strategic transactions and investments and is pursuing a formal process to unlock the value of its portfolio by monetizing its assets and ultimately distributing net proceeds to stockholders in the form of cash or equity.

For more information please visit https://www.pdl.com/

Contact


PDL BioPharma, Inc.
932 Southwood Blvd.
Incline Village, NV 89451
USA
 
Tel +1 775-832-8500
Fax +1 775-832-8501
 
LENSAR, Inc.
2800 Discovery Drive
Orlando, FL 32826
USA
 
Tel. +1 888-536-7271

E-mail: info@lensar.com

Web Site: www.lensar.com

Copyright © 2020 SPIE EuropeDesigned by Kestrel Web Services